GlassScriptPhysician profile
Eric J Melancon
NPI 1609955137
$8,662.91
in general payments reported to CMS, 2019-2025
45 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $454 · 2021: $923 · 2022: $1,311 · 2023: $1,530 · 2024: $1,298 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,507.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,684.29 | 2019-2025 | |
| Novo Nordisk INC | $1,238.95 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $759.17 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $569.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corium, LLC | $407.18 | 2022-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $363.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $357.75 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $328.39 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $211.16 | 2019-2025 | Unithroid |
| Takeda Pharmaceuticals U.S.A., INC. | $188.63 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $186.59 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $156.28 | 2019-2023 | Belsomra, Lagevrio |
| Teva Pharmaceuticals USA, INC. | $150.25 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $144.59 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.79 | 2022-2025 | Caplyta |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $137.19 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.50 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $110.36 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.33 | 2019-2024 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $103.63 | 2020-2023 | Linzess |
| Tolmar, INC. | $100.78 | 2024-2025 | Jatenzo |
| E.R. Squibb & Sons, L.L.C. | $95.88 | 2019-2024 | Eliquis |
| Glaxosmithkline, LLC. | $94.09 | 2020-2023 | Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $87.80 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $81.40 | 2023-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $63.70 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $56.26 | 2019-2022 | |
| Axsome Therapeutics, INC. | $54.79 | 2025 | Auvelity |
| Lundbeck LLC | $53.21 | 2023-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $46.84 | 2023-2024 | Zoryve, Seglentis, Livalo |
| Arbor Pharmaceuticals, INC. | $46.41 | 2020-2021 | |
| Mylan Specialty L.P. | $46.11 | 2019-2020 | |
| Astellas Pharma US INC | $45.09 | 2019-2022 | |
| Amarin Pharma, INC. | $41.23 | 2019-2022 | |
| Dexcom, INC. | $39.66 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $35.22 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Zyla Life Sciences, INC. | $32.92 | 2019 | |
| Shire North American Group INC | $31.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.80 | 2021-2024 | |
| Abbott Laboratories | $27.14 | 2021-2023 | Freestyle Libre 3 |
| Viatris Specialty LLC | $21.70 | 2025 | Yupelri |
| Medtronic Minimed, INC. | $18.98 | 2019 | |
| Acella Pharmaceuticals, LLC | $17.42 | 2025 | NP Thyroid 60 |
| Ironshore Pharmaceuticals INC. | $15.62 | 2019 | |
| Eisai INC. | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Melancon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.